Cholangiocarcinoma

Howard Masuoka, Gregory J. Gores, Charles B. Rosen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cholangiocarcinoma (CCA) is a rare primary hepatic neoplasm that arises from malignant transformation of the biliary epithelium. Chronic inflammation of the biliary tree as in primary sclerosing cholangitis (PSC), is a risk factor for the development of CCA. Hilar CCA usually presents with obstructive jaundice. Surgical resection and liver transplantation in carefully selected patients with extrahepatic CCA are the only curative modalities currently available. Unfortunately, most tumors are unresectable at the time of presentation. Biliary stenting, chemotherapy, radiation therapy, and photodynamic therapy (PDT) are palliative therapies for CCA. Liver transplantation following neoadjuvant therapy has emerged as an effective therapy for patients with unresectable hilar cholangiocarcinoma or hilar cholangiocarcinoma arising in PSC. Pre-transplant evaluation includes an extensive evaluation for metastatic disease. Pre-liver transplant care includes managing side effects of neoadjuvant therapy, maintaining adequate biliary drainage and promptly treating episodes of acute cholangitis. Post-liver transplant care is similar to that for transplantation for other diseases except for monitoring for recurrent CCA and vigilance for the development of late vascular complications due to neoadjuvant therapy.

Original languageEnglish (US)
Title of host publicationMedical Care of the Liver Transplant Patient: 4th Edition
PublisherWiley-Blackwell
Pages133-144
Number of pages12
ISBN (Print)9781444335910
DOIs
StatePublished - Mar 28 2012
Externally publishedYes

Fingerprint

Cholangiocarcinoma
Klatskin Tumor
Neoadjuvant Therapy
Sclerosing Cholangitis
Transplants
Liver Transplantation
Cholangitis
Obstructive Jaundice
Liver
Photochemotherapy
Biliary Tract
Liver Neoplasms
Palliative Care
Blood Vessels
Drainage
Radiotherapy
Epithelium
Transplantation
Inflammation
Drug Therapy

Keywords

  • Acute cholangitis
  • Biliary stenting
  • Biliary stricture
  • Cholangiocarcinoma
  • Liver transplantation
  • Living-donor liver transplantation
  • Neoadjuvant therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Masuoka, H., Gores, G. J., & Rosen, C. B. (2012). Cholangiocarcinoma. In Medical Care of the Liver Transplant Patient: 4th Edition (pp. 133-144). Wiley-Blackwell. https://doi.org/10.1002/9781444398441.ch12

Cholangiocarcinoma. / Masuoka, Howard; Gores, Gregory J.; Rosen, Charles B.

Medical Care of the Liver Transplant Patient: 4th Edition. Wiley-Blackwell, 2012. p. 133-144.

Research output: Chapter in Book/Report/Conference proceedingChapter

Masuoka, H, Gores, GJ & Rosen, CB 2012, Cholangiocarcinoma. in Medical Care of the Liver Transplant Patient: 4th Edition. Wiley-Blackwell, pp. 133-144. https://doi.org/10.1002/9781444398441.ch12
Masuoka H, Gores GJ, Rosen CB. Cholangiocarcinoma. In Medical Care of the Liver Transplant Patient: 4th Edition. Wiley-Blackwell. 2012. p. 133-144 https://doi.org/10.1002/9781444398441.ch12
Masuoka, Howard ; Gores, Gregory J. ; Rosen, Charles B. / Cholangiocarcinoma. Medical Care of the Liver Transplant Patient: 4th Edition. Wiley-Blackwell, 2012. pp. 133-144
@inbook{6184cd643343496495a59ec4cdc582ab,
title = "Cholangiocarcinoma",
abstract = "Cholangiocarcinoma (CCA) is a rare primary hepatic neoplasm that arises from malignant transformation of the biliary epithelium. Chronic inflammation of the biliary tree as in primary sclerosing cholangitis (PSC), is a risk factor for the development of CCA. Hilar CCA usually presents with obstructive jaundice. Surgical resection and liver transplantation in carefully selected patients with extrahepatic CCA are the only curative modalities currently available. Unfortunately, most tumors are unresectable at the time of presentation. Biliary stenting, chemotherapy, radiation therapy, and photodynamic therapy (PDT) are palliative therapies for CCA. Liver transplantation following neoadjuvant therapy has emerged as an effective therapy for patients with unresectable hilar cholangiocarcinoma or hilar cholangiocarcinoma arising in PSC. Pre-transplant evaluation includes an extensive evaluation for metastatic disease. Pre-liver transplant care includes managing side effects of neoadjuvant therapy, maintaining adequate biliary drainage and promptly treating episodes of acute cholangitis. Post-liver transplant care is similar to that for transplantation for other diseases except for monitoring for recurrent CCA and vigilance for the development of late vascular complications due to neoadjuvant therapy.",
keywords = "Acute cholangitis, Biliary stenting, Biliary stricture, Cholangiocarcinoma, Liver transplantation, Living-donor liver transplantation, Neoadjuvant therapy",
author = "Howard Masuoka and Gores, {Gregory J.} and Rosen, {Charles B.}",
year = "2012",
month = "3",
day = "28",
doi = "10.1002/9781444398441.ch12",
language = "English (US)",
isbn = "9781444335910",
pages = "133--144",
booktitle = "Medical Care of the Liver Transplant Patient: 4th Edition",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Cholangiocarcinoma

AU - Masuoka, Howard

AU - Gores, Gregory J.

AU - Rosen, Charles B.

PY - 2012/3/28

Y1 - 2012/3/28

N2 - Cholangiocarcinoma (CCA) is a rare primary hepatic neoplasm that arises from malignant transformation of the biliary epithelium. Chronic inflammation of the biliary tree as in primary sclerosing cholangitis (PSC), is a risk factor for the development of CCA. Hilar CCA usually presents with obstructive jaundice. Surgical resection and liver transplantation in carefully selected patients with extrahepatic CCA are the only curative modalities currently available. Unfortunately, most tumors are unresectable at the time of presentation. Biliary stenting, chemotherapy, radiation therapy, and photodynamic therapy (PDT) are palliative therapies for CCA. Liver transplantation following neoadjuvant therapy has emerged as an effective therapy for patients with unresectable hilar cholangiocarcinoma or hilar cholangiocarcinoma arising in PSC. Pre-transplant evaluation includes an extensive evaluation for metastatic disease. Pre-liver transplant care includes managing side effects of neoadjuvant therapy, maintaining adequate biliary drainage and promptly treating episodes of acute cholangitis. Post-liver transplant care is similar to that for transplantation for other diseases except for monitoring for recurrent CCA and vigilance for the development of late vascular complications due to neoadjuvant therapy.

AB - Cholangiocarcinoma (CCA) is a rare primary hepatic neoplasm that arises from malignant transformation of the biliary epithelium. Chronic inflammation of the biliary tree as in primary sclerosing cholangitis (PSC), is a risk factor for the development of CCA. Hilar CCA usually presents with obstructive jaundice. Surgical resection and liver transplantation in carefully selected patients with extrahepatic CCA are the only curative modalities currently available. Unfortunately, most tumors are unresectable at the time of presentation. Biliary stenting, chemotherapy, radiation therapy, and photodynamic therapy (PDT) are palliative therapies for CCA. Liver transplantation following neoadjuvant therapy has emerged as an effective therapy for patients with unresectable hilar cholangiocarcinoma or hilar cholangiocarcinoma arising in PSC. Pre-transplant evaluation includes an extensive evaluation for metastatic disease. Pre-liver transplant care includes managing side effects of neoadjuvant therapy, maintaining adequate biliary drainage and promptly treating episodes of acute cholangitis. Post-liver transplant care is similar to that for transplantation for other diseases except for monitoring for recurrent CCA and vigilance for the development of late vascular complications due to neoadjuvant therapy.

KW - Acute cholangitis

KW - Biliary stenting

KW - Biliary stricture

KW - Cholangiocarcinoma

KW - Liver transplantation

KW - Living-donor liver transplantation

KW - Neoadjuvant therapy

UR - http://www.scopus.com/inward/record.url?scp=84885545365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885545365&partnerID=8YFLogxK

U2 - 10.1002/9781444398441.ch12

DO - 10.1002/9781444398441.ch12

M3 - Chapter

AN - SCOPUS:84885545365

SN - 9781444335910

SP - 133

EP - 144

BT - Medical Care of the Liver Transplant Patient: 4th Edition

PB - Wiley-Blackwell

ER -